- Conditions
- Heparin-induced Thrombocytopenia
- Interventions
- Danaparoid Sodium, Argatroban
- Drug
- Lead sponsor
- Aspen Global Incorporated
- Industry
- Eligibility
- 2 Weeks to 100 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Minneapolis, Minnesota • Durham, North Carolina + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 92
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Trauma Injury
- Interventions
- Prothrombin Complex Concentrate, Human, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant])
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 14 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- fitusiran, Bypassing agents
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- fitusiran, factor concentrates
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
- Conditions
- Factor VIII Deficiency, Congenital
- Interventions
- Emicizumab
- Drug
- Lead sponsor
- Indiana Hemophilia &Thrombosis Center, Inc.
- Other
- Eligibility
- 5 Years to 45 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hemophilia B
- Interventions
- AskBio009
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 11 more
- Conditions
- Hemophilia B, Hemophilia A
- Interventions
- Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 13
- States / cities
- Palo Alto, California • San Francisco, California • Stanford, California + 7 more
- Conditions
- Hemophilia B
- Interventions
- verbrinacogene setparvovec
- Genetic
- Lead sponsor
- Spur Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan
- Conditions
- Hemophilia
- Interventions
- Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013, Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
- Biological
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 27
- States / cities
- San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more
- Conditions
- Hemophilia B
- Interventions
- BeneFIX
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Detroit, Michigan • New Brunswick, New Jersey + 3 more
- Conditions
- Severe Hemophilia B
- Interventions
- Factor IX (rFIXFc), rFIX
- Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more
- Conditions
- Hemophilia B
- Interventions
- Not listed
- Lead sponsor
- Bloodworks
- Other
- Eligibility
- 16 Years and older · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • New Orleans, Louisiana + 2 more
- Conditions
- Hemophilia B
- Interventions
- Gene Transfer, scAAV2/8-LP1-hFIXco
- Genetic · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 3
- States / cities
- Stanford, California • Memphis, Tennessee • Temple, Texas
- Conditions
- Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass, Platelet Transfusion, Arrythmia, Cardiac, Mortality
- Interventions
- Platelet Transfusion, FFP and Cryoprecipitate, PRBC and cell saver Transfusion, Factor Concentrate (Bebulin)
- Biological
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Day to 3 Months
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hemophilia B
- Interventions
- CSL222 (AAV5-hFIXco-Padua)
- Genetic
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 4
- States / cities
- San Diego, California • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Anticoagulant-related Major Bleed
- Interventions
- Andexanet alfa, 4F-PCC
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 5,480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Agoura Hills, California
- Conditions
- HIV Infections, Hemophilia A
- Interventions
- Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years and older · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 7
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
- Conditions
- Hemophilia B
- Interventions
- Not listed
- Lead sponsor
- Spark Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- Hemophilia B standard half-life, Hemophilia B extended half-life, Hemophilia A standard half-life, Hemophilia A extended half-life
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- Not listed
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Las Vegas, Nevada • Fort Worth, Texas
- Conditions
- Hemophilia B
- Interventions
- SPK-9001
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Sacramento, California • Jackson, Mississippi • Madison, Mississippi + 2 more
- Conditions
- Haemostasis, Congenital Bleeding Disorder, Haemophilia B
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Interventions
- activated recombinant human factor VII, factor IX, factor VIII
- Drug · Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
- Conditions
- Hemophilia B
- Interventions
- FLT180a
- Biological
- Lead sponsor
- University College, London
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee